Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Centrexion acquires three analgesics from BI in deal worth up to $897mm

Executive Summary

Start-up Centrexion Therapeutics Corp. (chronic pain therapeutics) acquired three analgesics from Boehringer Ingelheim GMBH. The product acquisitions will strengthen Centrexion's existing pipeline (lead is currently CNTX4975; direct injection for pain) which is based on a patented exclusive injectable trans-capsaicin.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product Purchase
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies